Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elimination of visceral leishmaniasis as a public health problem in Bangladesh: Lessons learned and questions remaining.

PLoS neglected tropical diseases·2026
Same author

Cytokine storm in severe bacterial infections: A Mini-Review of molecular insights and treatment strategies.

Molecular biology reports·2026
Same author

The Safety and Efficacy of an Immunomodulator Garlic-Based Cream (LeishG1) for Treating Uncomplicated Cutaneous Leishmaniasis: A Single-Blind, Multi-Center Study.

Health science reports·2025
Same author

The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities.

Parasites & vectors·2025
Same author

Erysipeloid Cutaneous Leishmaniasis in the Old World: A Systematic Review.

International journal of dermatology·2025
Same author

Leishmaniasis.

Nature reviews. Disease primers·2025

Related Experiment Video

Updated: May 12, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Case study for a vaccine against leishmaniasis.

Jorge Alvar1, Simon L Croft, Paul Kaye

  • 1Drugs for Neglected Disease initiative (DNDi) 15, Chemin Louis-Dunant, 1202 Geneva, Switzerland.

Vaccine
|April 20, 2013
PubMed
Summary

Developing a single leishmaniasis vaccine is a unique challenge due to the disease complex. Promising candidates show potential for both prevention and therapeutic use in humans.

More Related Videos

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

Related Experiment Videos

Last Updated: May 12, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

Area of Science:

  • Parasitology
  • Vaccinology
  • Tropical Diseases

Background:

  • Leishmaniasis is a complex disease caused by related parasite species.
  • Existing research explores single vaccines for multiple leishmaniasis forms.
  • Leishmaniasis vaccines show potential for prophylactic and therapeutic applications.

Purpose of the Study:

  • To review the unique aspects of leishmaniasis vaccine development.
  • To highlight the potential for a single vaccine against multiple parasite species.
  • To discuss the dual prophylactic and therapeutic possibilities of leishmaniasis vaccines.

Main Methods:

  • Review of current immunization approaches for leishmaniasis.
  • Analysis of vaccine candidates using parasite antigens or vector extracts.
  • Evaluation of adjuvant use in vaccine formulations.

Main Results:

  • Several vaccine candidates have demonstrated efficacy in human trials for prevention and treatment.
  • Promising animal data exists for multiple vaccine candidates.
  • A robust pipeline of leishmaniasis vaccine candidates is under development.

Conclusions:

  • Leishmaniasis vaccine development presents a unique case study.
  • Further investment in leishmaniasis vaccine research is scientifically and epidemiologically justified.
  • The development of effective leishmaniasis vaccines is a critical goal.